Journal Center, Shandong First Medical University (Shandong Academy of Medical Sciences), China.
J Cancer Res Ther. 2024 Apr 1;20(2):592-598. doi: 10.4103/jcrt.jcrt_1627_23. Epub 2024 Apr 30.
To analyze the characteristics of retracted oncology papers from Chinese scholars and the reasons for retraction.
Data on retracted oncology papers from Chinese scholars published from 2013 to 2022 were retrieved from the Retraction Watch database. The retraction number and annual distribution, article types, reasons for retraction, retraction time delay, publishers, and journal characteristics of the retracted papers were analyzed.
A total of 2695 oncology papers from Chinese scholars published from 2013 to 2022 had been retracted. The majority of these papers were published from 2017 to 2020. In terms of article type, 2538 of the retracted papers were research articles, accounting for 94.17% of the total number of retracted papers. The main reasons for retraction were data, result, and image problems, duplicate publication, paper mills, author- and third-party-related reasons, plagiarism, false reviews, and method errors. The retraction time delay for the retracted papers ranged from 0 to 3582 days (median, 826 days). The retractions mainly occurred within the first 4 years after publication. A total of 77 publishers were involved in the retracted papers. In terms of journal distribution, 394 journals were involved in the retracted papers, of which 368 (93.40%) were included in the SCI database. There were 243 journals with an impact factor of <5 (66.03%).
In the field of oncology, the annual distribution of retracted papers from Chinese scholars exhibited first an increasing and subsequently a decreasing trend, reaching a peak in 2019, indicating an improvement in the status of retraction after 2021. The main type of the retracted papers was research article, and the main reason for retraction was academic misconduct. The retractions were mainly concentrated in several major publishers and periodicals in Europe and the United States. Most of the journals had low-impact factors.
分析中国学者撤稿肿瘤学论文的特征及撤稿原因。
检索 Retraction Watch 数据库 2013 年至 2022 年中国学者发表的撤稿肿瘤学论文，分析撤稿论文的撤稿数量和年度分布、论文类型、撤稿原因、撤稿时间延迟、出版商和期刊特征。
共检索到 2013 年至 2022 年中国学者发表的 2695 篇撤稿肿瘤学论文。其中，2017 年至 2020 年发表的论文最多。从论文类型来看，2538 篇为研究型论文，占撤稿论文总数的 94.17%。撤稿的主要原因是数据、结果和图像问题、重复发表、论文工厂、作者和第三方相关原因、抄袭、虚假评论和方法错误。撤稿论文的撤稿时间延迟从 0 至 3582 天（中位数为 826 天）不等。撤稿主要发生在发表后 4 年内。共涉及 77 个出版商。从期刊分布来看，394 种期刊涉及撤稿论文，其中 368 种（93.40%）被 SCI 数据库收录。有 243 种期刊的影响因子<5（66.03%）。
在肿瘤学领域，中国学者撤稿论文的年度分布呈先增后减的趋势，2019 年达到峰值，表明 2021 年后撤稿状况有所改善。撤稿论文主要类型为研究型论文，撤稿主要原因为学术不端行为。撤稿主要集中在欧美几家主要出版商和期刊上。大多数期刊的影响因子较低。
